TIVO-3: Age-related tolerability outcomes of tivozanib versus sorafenib in metastatic relapsed or refractory renal cell carcinoma, a subgroup analysis of the TIVO-3 clinical trial.

被引：0

作者：

Escudier, Bernard

Rini, Brian I.

Pal, Sumanta K.

McDermott, David F.

Porta, Camillo

Verzoni, Elena

Atkins, Michael B.

Needle, Michael N.

Hutson, Thomas E.

机构：

[1] Gustave Roussy, Villejuif, France

[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[3] City Hope, Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA

[4] Harvard Canc Ctr, Dana Farber, Beth Israel Deaconess Med Ctr, Boston, MA USA

[5] Univ Bari A Moro, Bari, Italy

[6] Policlin Consorziale Bari, Bari, Italy

[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[8] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[9] Aveo Oncol, Boston, MA USA

[10] Texas A&M Coll Med, Bryan, TX USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e16553

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16553

引用

页数：3